Sangamo Therapeutics, Inc.
-
Website
-
Code
SGMO
-
Size
51 to 200 employees
-
Industries
Passionate. Guided by Science. Results Oriented.
Sangamo was founded in 1995 as Sangamo BioSciences, Inc. in order to research new technologies for genome editing. Over two decades, Sangamo's scientists developed the most advanced, flexible and precise technologies available for gene-based therapies. In 2017, Sangamo is conducting new human clinical trials, including the first ever in vivo human genome editing studies. Reflecting this focus on the clinical development of new genomic therapies, in 2017 the Company announced a new name, Sangamo Therapeutics.
For Sangamo Therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. The Company's scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. Sangamo expects its scientific investment will reliably generate new programs for human clinical development.